Gastrointestinal Involvement in Mantle Cell Lymphoma (MCL). A Prospective Clinical, Endoscopical, Pathological and Molecular Study.

Abstract Objective: to investigate the clinical, endoscopical, microscopical and molecular involvement of the GI tract in a prospective series of MCL. Methods: 13 patients with MCL have been prospectively and consecutively entered in a staging workup that included upper and lower endoscopy of the GI tract. Multiple biopsies of the stomach and colon were taken from pathologic mucosa and also from macroscopically normal mucosa. Specimens were assessed with immunohistochemistry (IHC), FISH and PCR. Results: Only 1 patient presented with GI symptoms at diagnosis. Endoscopy: Upper GI: abnormal mucosa in 5 cases (38%); Lower GI: abnormal mucosa in 6 cases (45%): mild colitis in 1, multiple micropolyps in 3, a large polyp and multiple micropolyps in 1 and three large polyps with normal mucosa in 1. As a whole, 9 patients (70%) had upper or lower endoscopic findings. Pathology: 10 cases (77%) had microscopic infiltration by MCL of the upper GI tract and 10 cases (77%) of the lower GI tract. As a whole, all but one patient (92%) were found to have microscopic infiltration of the GI tract. All positive cases for CD20 and CD5 were positive for cyclin D1. The PCR product showed a clear monoclonal peak in 12 out of 19 samples, giving a sensitivity of 63.5% compared with IHC. FISH was positive in 7 out of 11 samples (sensitivity of 64% compared with IHC). All but one case with endoscopic abnormalities had GI microscopic infiltration by MCL and 67% of cases with normal endoscopy were found to have GI tract infiltration by MCL. Conclusions: In our series, GI involvement by MCL was detected in almost all patients. All patients with endoscopic abnormalities had infiltration by MCL at the microscopic level. In 2/3 of the patients with normal endoscopy, GI tract involvement could be demonstrated at the microscopic level. IHC with cyclin D1 was more efficient than FISH and PCR as a diagnostic tool in this setting.

Download Full-text

Investigation of oral, gastric, and duodenal microbiota in patients with upper gastrointestinal symptoms

Journal of Investigative Medicine ◽

10.1136/jim-2020-001642 ◽

2020 ◽

Vol 69 (4) ◽

pp. 870-877

Author(s):

Jorge Cervantes ◽

Majd Michael ◽

Bo-Young Hong ◽

Aden Springer ◽

Hua Guo ◽

...

Keyword(s):

Gastrointestinal Symptoms ◽

Microbiota Composition ◽

Gi Tract ◽

Upper Gi ◽

Functional Gi Disorders ◽

Gi Symptoms ◽

Dyspeptic Symptoms ◽

Upper Gastrointestinal Symptoms ◽

Upper Gastrointestinal ◽

Gastric Microbiota

Disease-associated alterations of the intestinal microbiota composition, known as dysbiosis, have been well described in several functional gastrointestinal (GI) disorders. Several studies have described alterations in the gastric microbiota in functional dyspepsia, but very few have looked at the duodenum.Here, we explored the upper GI tract microbiota of inpatients with upper GI dyspeptic symptoms, and compared them to achalasia controls, as there is no indication for an esophagogastroduodenoscopy in healthy individuals.We found differences in the microbiota composition at the three sites evaluated (ie, saliva, stomach and duodenum). Changes observed in patients with dyspepsia included an increase in Veillonella in saliva, an oral shift in the composition of the gastric microbiota, and to some degree in the duodenum as well, where an important abundance of anaerobes was observed. Metabolic function prediction identified greater anaerobic metabolism in the stomach microbial community of patients with dyspepsia. Proton pump inhibitor use was not associated with any particular genus. Co-abundance analysis revealed Rothia as the main hub in the duodenum, a genus that significantly correlated with the relative abundance of Clostridium, Haemophilus, and Actinobacillus.We conclude that patients with upper GI symptoms consistent with dyspepsia have alterations in the microbiota of saliva, the stomach, and duodenum, which could contribute to symptoms of functional GI disorders.

Download Full-text

Assessment of Whole Gut Motility in Adolescents Using the Wireless Motility Capsule Test

10.21203/rs.3.rs-749533/v1 ◽

2021 ◽

Author(s):

Tanja Fritz ◽

Christoph Huenseler ◽

Ilse Broekaert

Keyword(s):

Invasive Procedure ◽

Colonic Transit ◽

Gi Tract ◽

Diagnostic Challenge ◽

Upper Gi ◽

Functional Gi Disorders ◽

Transit Times ◽

Intestinal Dysmotility ◽

Gi Symptoms ◽

Wireless Motility Capsule

Abstract Functional gastrointestinal (GI) disorders are often associated with intestinal dysmotility representing a diagnostic challenge. A relatively new method is the wireless motility capsule (WMC) test, which continuously measures pH, pressure, temperature and regional transit times as it passes through the GI tract. In adults, the WMC test was approved for use in the diagnosis of gastroparesis and constipation by assessing GI transit and contractility. We performed the WMC test in nine adolescent patients aged 12–17 years with functional GI symptoms from July 2017 until February 2019. Abnormal transit times were detected in four patients. Three patients showed abnormal transit times of the upper GI tract, in two cases contractility analysis revealed gastroparesis, in one patient abnormal colonic transit was detected. Conclusion: The WMC test is a minimally invasive procedure with potential to expand future diagnostic opportunities for paediatric patients with functional GI disorders and suspected motility disturbances.

Download Full-text

INTERVENTIONAL TRAINING MODEL FOR FLEXIBLE ENDOSCOPY IN POSTOPERATIVELY ALTERED ANATOMY OF THE UPPER GI TRACT

10.1055/s-0040-1704783 ◽

2020 ◽

Author(s):

K Koch ◽

U Schweizer ◽

B Mothes ◽

D Wichmann ◽

KE Grund

Keyword(s):

Training Model ◽

Flexible Endoscopy ◽

Gi Tract ◽

Upper Gi ◽

Upper Gi Tract

Download Full-text

Enterogastric Reflux: an Uncommon Diagnosis Analyzed by Hepatobiliary Imaging

Journal of Case Reports in Medicine ◽

10.25149/jcrm.v8i2.178 ◽

2019 ◽

Vol 8 (2) ◽

Author(s):

Peter Wang

Keyword(s):

Abdominal Pain ◽

Digestive Enzymes ◽

Gallbladder Disease ◽

Hepatobiliary Scintigraphy ◽

Hepatobiliary Imaging ◽

Upper Gi ◽

Gi Symptoms ◽

Upper Abdominal ◽

Enterogastric Reflux

Enterogastric reflux (EGR) is the reflux of bile and digestive enzymes from the small bowel into the stomach. While it is a normal physiologic process in small amounts, excessive reflux and chronic EGR can cause upper GI symptoms often mimicking more common diseases such as gallbladder disease and GERD that often leads to its underdiagnosis. Identifying EGR is significant as it has been associated with the development of gastroesophogeal pathology including gastritis, esophagitis, ulcers, and mucosal metaplasia. This article presents a 22-year-old male with enterogastric reflux causing upper abdominal pain and will discuss the role of hepatobiliary scintigraphy in its diagnosis.

Download Full-text

A147 PRIMARY COLONIC MANTLE CELL LYMPHOMA: A RARE ENTITY

Journal of the Canadian Association of Gastroenterology ◽

10.1093/jcag/gwab002.145 ◽

2021 ◽

Vol 4 (Supplement_1) ◽

pp. 138-140

Author(s):

K Donaldson ◽

S Nassiri ◽

D Chahal ◽

M F Byrne

Keyword(s):

Case Report ◽

Cyclin D1 ◽

Mantle Cell Lymphoma ◽

Transverse Colon ◽

Cell Lymphoma ◽

Rapid Progression ◽

Rare Entity ◽

Gi Bleeding ◽

Gi Tract ◽

Mantle Cell

Abstract Background Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphoma (NHL), often diagnosed at later stages with secondary gastrointestinal (GI) involvement. Primary GI MCL is rare and is not often discussed in the literature. Aims To increase awareness of a rare condition that is likely to be encountered but can be challenging to diagnose. Methods Case report and review of the literature. Results Case Report A 78-year-old man with multiple untreated vascular risk factors including atrial fibrillation and type 2 diabetes presented with acute onset left hemiplegia, dysarthria, and imaging consistent with a left pontine stroke. As part of his workup he underwent a CT abdomen/pelvis identifying an 11 x 5 cm intraluminal mass in the transverse colon. Previous screening colonoscopies, for family history of colon cancer, were notable for tubular adenomas without high-grade dysplasia at 13, 12, 10, 7, and 2 years prior to admission. The patient had 16 pounds of weight loss without other constitutional symptoms, change in bowel habits or evidence of GI bleeding. Bloodwork was notable for microcytic anemia (Hemoglobin 91 g/L, MCV 75 fL), from a normal baseline one year prior, without other cytopenias. C-reactive protein (44 mg/L) and GGT (164 U/L) were elevated. Other liver enzymes, lactate dehydrogenase, and electrolytes were normal. Colonoscopy revealed numerous polypoid lesions throughout the entire colon and a large non-obstructive mass with submucosal appearance in the transverse colon. Biopsies were taken from the large mass and one of the smaller polypoid lesions. Histology showed a sheet-like infiltrate of small lymphocytes within the lamina propria. Immunohistochemical staining was positive for CD20, BCL2, Cyclin D1, equivocal for CD5, and negative for BCL6 and CD3. Ki67 index approached 30%. A diagnosis of colonic MCL was made. Literature Review Primary MCL of the GI tract is rare, accounting for only 1 to 4% of all GI malignancies. There is a male and Caucasian predominance with a median age of 68 years at diagnosis. Presenting complaints may include abdominal pain, anorexia, and GI bleeding. Typical endoscopic features are small nodular or polypoid tumors, between 2mm and 2 cm in size, along one or more segments of the GI tract referred to as multiple lymphomatous polyposis (MLP). A single colonic mass is infrequently seen, highlighting the importance of endoscopy for diagnosis, as subtle findings may be missed on radiographic evaluation. Biopsies for immunohistochemistry are essential to distinguish MCL from other NHLs, as almost all cases express cyclin D1. Despite aggressive immunochemotherapy, prognosis is often poor due to MCL’s rapid progression and early relapse. Conclusions Primary GI MCL is a rare entity. Awareness is essential as evaluation and management differ from lymphoma at other sites, and other GI malignancies. Funding Agencies None

Download Full-text